Venrock

Venrock is a Palo Alto-based venture capital firm founded in 1969 as the venture capital arm of the Rockefeller family. It concentrates on seed and early-stage investments in technology and healthcare, with interests spanning information technology, life sciences and related sectors in the United States. The firm has supported a broad portfolio of companies, including Apple, Intel, Illumina, DoubleClick, Athenahealth, Gilead Sciences, Nest, SlideShare and Tudou. Venrock emphasizes long-term partnerships with entrepreneurs, combining hands-on venture support with rigorous data analysis to help startups grow into enduring companies.

Brian Ascher

Partner

Harry Barber

Investor

Ethan Batraski

Partner

Nick Beim

Partner

Racquel Bracken

Partner

Paul Dossa

Investor

Tony Evnin

Partner

Steven Goldby

Partner

Andrew Gottesdiener

Investor

Kenneth Greenberg

Partner

Ken Greenberg

Investor

Manjinder Kandola

Investor

Bob Kocher

Partner

Bong Koh

Investor

Mariana Mihalusova

Vice President

Bryan Roberts

Partner

Camille Samuels

Partner

Nimish Shah

Investor

Ganesh Srinivasan

Partner

Ganesh Srinivasan

Partner

Michael Tyrrell

Partner

Andy Wardle

Investor

Past deals in California

Surrozen

Post in 2025
Surrozen, Inc. is a clinical-stage biopharmaceutical company based in South San Francisco, California, focused on developing targeted regenerative antibodies to enhance tissue and organ repair in response to serious diseases. Founded in 2015, the company specializes in modulating the Wnt pathway, a crucial mediator of tissue regeneration, through its innovative antibody platforms that target specific organs and tissues. Notable programs include SZN-043, designed to stimulate liver regeneration in both acute and chronic liver diseases, and SZN-1326, aimed at repairing damaged epithelial tissue in patients with inflammatory bowel disease. Surrozen's approach extends to multiple organ systems, with potential applications in the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system.

Auditoria.AI

Series B in 2025
Auditoria.AI, Inc. is a technology company based in Santa Clara, California, founded in 2019. It specializes in providing innovative financial solutions for enterprise accounting and audit, utilizing advanced artificial intelligence and machine learning technologies. The company focuses on enhancing compliance and automating finance back-office processes through its flagship product, which employs natural language processing and predictive analytics. By streamlining operations and reducing redundancy, Auditoria.AI aims to support finance teams in making informed, data-driven decisions and improving overall efficiency.

Cidara Therapeutics

Post in 2024
Cidara Therapeutics is a biotechnology company dedicated to developing novel anti-infectives. Its primary focus is rezafungin acetate, an antifungal for treating serious invasive fungal infections. Additionally, it advances the Cloudbreak platform to develop antiviral therapies using Fc-conjugates.

Element Biosciences

Series D in 2024
Element Biosciences develops innovative genetic analysis tools for research and diagnostic markets. Founded in 2017, the company specializes in a disruptive DNA sequencing technology that offers high-quality data, workflow flexibility, and affordable access to next-generation sequencing.

Tenaya Therapeutics

Post in 2024
Tenaya Therapeutics is a preclinical-stage biotechnology company focused on developing therapies for heart disease and heart failure. It operates three product platforms: cellular regeneration, which aims to regenerate heart tissue by reprogramming cardiac fibroblasts into cardiomyocytes via delivery of proprietary transcription factors; gene therapy, which targets cardiac fibroblasts to deliver therapeutic payloads; and precision medicine, which enables personalized approaches to treat heart disease. Founded in 2016 and headquartered in South San Francisco, California, Tenaya seeks to address the underlying cellular pathologies of diseased myocardium with curative therapies that advance from discovery through development.

Adverum Biotechnologies

Post in 2024
Adverum Biotechnologies is a clinical-stage company focused on developing gene therapies to treat ocular diseases. Its pipeline includes ADVM-022 for wet age-related macular degeneration, ADVM-043 for alpha-1 antitrypsin deficiency, and preclinical candidates for other indications.

SmithRx

Series C in 2024
Founded in San Francisco in 2016, SmithRx specializes in designing and managing custom pharmacy benefit plans for companies. It leverages a modern technology platform to deliver flexibility, efficiency, and customer satisfaction, aligning incentives through data analytics.

RefleXion Medical

Venture Round in 2023
RefleXion Medical Inc. is a medical equipment company based in Hayward, California, focused on revolutionizing cancer treatment through its biologically-guided radiotherapy system (BgRT). This innovative technology allows tumors to continuously signal their location during treatment, enabling the simultaneous targeting of multiple tumors, even in cases of metastasized cancer. The RefleXion X1 machine is cleared for various forms of radiotherapy, including stereotactic body radiotherapy, stereotactic radiosurgery, and intensity-modulated radiotherapy. The BgRT system utilizes positron-emission tomography (PET) imaging data to synchronize tumor location information with the linear accelerator, allowing for real-time adjustments in treatment delivery with subsecond latency. RefleXion Medical has established strategic collaborations with Telix Pharmaceuticals Limited and HealthMyne Inc. since its incorporation in 2009.

ADARx Pharmaceuticals

Series C in 2023
ADARx Pharmaceuticals specializes in the development of RNA editing therapeutics. Founded in 2019, the company focuses on discovering and developing innovative treatments that utilize endogenous enzymes to precisely target and correct single point mutations in mRNA transcripts, restoring the production of functional proteins.

ORIC Pharmaceuticals

Post in 2023
ORIC Pharmaceuticals is a clinical-stage biopharmaceutical company dedicated to improving patients' lives by developing therapies that overcome resistance in cancer. Its lead product candidate, ORIC-101, targets the glucocorticoid receptor linked to resistance across various solid tumors. ORIC's second product candidate, ORIC-533, inhibits CD73 to address resistance to chemotherapy and immunotherapy. The company is also developing precision medicines targeting other cancer resistance mechanisms.

Carmot Therapeutics

Series E in 2023
Carmot Therapeutics, Inc. is a clinical-stage biotechnology company based in Berkeley, California, with an additional office in San Francisco. Founded in 2008, it focuses on discovering and developing innovative therapies for patients with metabolic diseases, including obesity and diabetes. Utilizing its proprietary Chemotype Evolution technology, Carmot Therapeutics aims to address the underlying causes of these conditions and accelerate the discovery of effective treatments. The company’s portfolio includes several clinical-stage drug candidates, such as CT-388 and CT-996, which are designed as GLP-1 receptor agonists for the treatment of obesity and type 2 diabetes, and CT-868, intended for type 1 diabetes patients who are overweight or obese. Through these efforts, Carmot Therapeutics seeks to create life-changing therapeutics that improve the health outcomes of individuals affected by metabolic diseases.

Vocera Communications

Post in 2023
Vocera Communications, Inc. specializes in providing secure and integrated communication and workflow solutions tailored for mobile workers across various sectors, including healthcare, hospitality, retail, energy, and education. The company’s offerings enhance communication and operational efficiency by integrating with existing clinical systems, such as electronic health records and nurse call systems. Vocera's product suite includes the Vocera Communication and Workflow System, which connects various communication devices, including hands-free and voice-controlled options, and the Vocera Care Experience software, designed to improve patient care quality and streamline manual tasks. Additionally, Vocera operates the Experience Innovation Network, collaborating with healthcare organizations to develop innovative solutions that improve patient and care team experiences. The company, founded in 2000 and headquartered in San Jose, California, serves approximately 1,700 healthcare facilities globally, including hospitals and clinics, and distributes its products through direct sales, resellers, and distributors.

Apogee Therapeutics

Series B in 2022
Apogee Therapeutics is a biotechnology company focused on developing therapies for immunological and inflammatory disorders. Based in San Francisco and founded in 2022, it aims to advance novel biologics to address patients’ unmet needs. The company pursues differentiated antibody programs targeting well-established mechanisms implicated in atopic dermatitis, chronic obstructive pulmonary disease, and related inflammatory and immunology indications, supported by antibody engineering to optimize half-life and other properties.

Terns Pharmaceuticals

Post in 2022
Founded in 2017, Terns Pharmaceuticals is a biopharmaceutical company dedicated to discovering and developing molecularly targeted, oral small-molecule drugs for treating cancer and liver diseases. Headquartered in Foster City, California with offices in Shanghai, China, the company focuses on advancing its pipeline of drugs optimized against clinically validated targets.

Dgraph Labs

Seed Round in 2022
Dgraph Labs is a software company that develops and operates a graph database designed for low-latency, real-time queries on large volumes of structured data. The database supports open-source use and enterprise deployments, including Slash Enterprise, a fully managed, serverless solution for workloads running on dedicated multi-zone clusters across AWS, Azure, or Google Cloud Platform. The platform enables efficient retrieval for real-time queries as well as semantic search, pattern matching, and fraud detection, helping organizations manage, represent, and visualize large datasets. Founded in 2016 and based in San Francisco, Dgraph Labs serves startups and larger enterprises seeking scalable graph data management.

The Public Health Company

Series A in 2022
The Public Health Company is a pioneering firm that specializes in biosecurity solutions, offering a SaaS-enabled platform designed for the management of bio-risks. Founded in 2020 and headquartered in Palo Alto, California, the company leverages advanced technology and expert knowledge to address the challenges of enterprise risk management. Its platform focuses on identifying and mitigating physical world threats across various applications, providing clients with actionable and predictive intelligence. This enables organizations to implement dynamic risk management strategies efficiently and effectively, enhancing their preparedness against potential biohazards.

RefleXion Medical

Venture Round in 2022
RefleXion Medical Inc. is a medical equipment company based in Hayward, California, focused on revolutionizing cancer treatment through its biologically-guided radiotherapy system (BgRT). This innovative technology allows tumors to continuously signal their location during treatment, enabling the simultaneous targeting of multiple tumors, even in cases of metastasized cancer. The RefleXion X1 machine is cleared for various forms of radiotherapy, including stereotactic body radiotherapy, stereotactic radiosurgery, and intensity-modulated radiotherapy. The BgRT system utilizes positron-emission tomography (PET) imaging data to synchronize tumor location information with the linear accelerator, allowing for real-time adjustments in treatment delivery with subsecond latency. RefleXion Medical has established strategic collaborations with Telix Pharmaceuticals Limited and HealthMyne Inc. since its incorporation in 2009.

SmithRx

Series B in 2022
Founded in San Francisco in 2016, SmithRx specializes in designing and managing custom pharmacy benefit plans for companies. It leverages a modern technology platform to deliver flexibility, efficiency, and customer satisfaction, aligning incentives through data analytics.

Decodable

Series A in 2022
Decodable is a serverless data integration and engineering platform focused on streaming data, founded in 2021 by Eric Sammer and headquartered in San Francisco, California. The company offers a software solution that enables applications and data engineers to construct complex data pipelines efficiently. Its platform facilitates seamless connections to various existing messaging, storage, and database systems, allowing users to rapidly collect, process, and deliver data to both offline and online systems. Through its innovative approach, Decodable aims to simplify the management of streaming data, enhancing the capabilities of organizations in handling real-time data flows.

Atom Computing

Series B in 2022
Atom Computing Inc. is a technology company based in Berkeley, California, focused on the development of scalable quantum computers utilizing individual atoms. Founded in 2018, the company leverages the quantum mechanical properties of these atoms to process information and tackle complex problems that are beyond the capabilities of traditional computing. Atom Computing's innovative approach enables precise control, scaling, and stabilization of atoms, allowing quantum engineers and researchers to conduct advanced calculations in various fields, including drug design, computational chemistry, and other areas of general computing.

Apogee Therapeutics

Series A in 2022
Apogee Therapeutics is a biotechnology company focused on developing therapies for immunological and inflammatory disorders. Based in San Francisco and founded in 2022, it aims to advance novel biologics to address patients’ unmet needs. The company pursues differentiated antibody programs targeting well-established mechanisms implicated in atopic dermatitis, chronic obstructive pulmonary disease, and related inflammatory and immunology indications, supported by antibody engineering to optimize half-life and other properties.

Skyryse

Series B in 2021
Skyryse develops FlightOS, a hardware and software operating system that enables safer, more capable, and accessible flight across various aircraft types. Founded in 2016, the company is headquartered in Los Angeles, California.

Stride Health

Series C in 2021
Stride Health, Inc. is a health benefits platform that specializes in providing affordable health coverage options for independent workers and part-time employees in the United States. The company offers a range of services, including dental plans, doctor and prescription insurance plans, and various health coverage options tailored to meet the needs of its customers. Stride Health simplifies the enrollment process by guiding users through selecting the most cost-effective health plans, aiming to optimize their tax benefits and enhance their take-home pay. Founded in 2013 and based in San Francisco, California, the company was previously known as Covered, Inc. and rebranded to Stride Health, Inc. in March 2013. Stride Health also provides personal advisory services to assist clients in navigating the complexities of their health insurance options.

Aadi Bioscience

Private Equity Round in 2021
Aadi Bioscience is a clinical-stage biopharmaceutical company developing precision therapies for cancers driven by mTOR pathway alterations. It focuses on targeted mTOR inhibitors to treat genetically defined cancers, including alterations in TSC1 or TSC2 genes, where conventional inhibitors have struggled with pharmacology, delivery, safety, or tumor targeting. The company is advancing ABI-009, a clinical-phase mTOR inhibitor intended for oncology indications as well as cardiovascular and metabolic contexts. Aadi aims to bring transformative therapies to patients with ultra-rare cancers such as PEComa, and it traces its origins to an earlier name, with its operations based in Pacific Palisades, California, and a founding year of 2011.

Atom Computing

Series A in 2021
Atom Computing Inc. is a technology company based in Berkeley, California, focused on the development of scalable quantum computers utilizing individual atoms. Founded in 2018, the company leverages the quantum mechanical properties of these atoms to process information and tackle complex problems that are beyond the capabilities of traditional computing. Atom Computing's innovative approach enables precise control, scaling, and stabilization of atoms, allowing quantum engineers and researchers to conduct advanced calculations in various fields, including drug design, computational chemistry, and other areas of general computing.

Element Biosciences

Series C in 2021
Element Biosciences develops innovative genetic analysis tools for research and diagnostic markets. Founded in 2017, the company specializes in a disruptive DNA sequencing technology that offers high-quality data, workflow flexibility, and affordable access to next-generation sequencing.

RayzeBio

Series C in 2021
RayzeBio, Inc. is a biotechnology company based in San Diego, California, founded in 2020. The company specializes in developing tumor-targeted small molecule medicines that leverage radioisotopes to improve cancer treatment outcomes. RayzeBio focuses on creating innovative radiopharmaceuticals, particularly utilizing alpha-emitting radioisotopes like Actinium-225, to target solid tumors effectively. With a robust pipeline of drug candidates, RayzeBio is committed to addressing significant market opportunities in oncology through late-stage clinical programs, development initiatives, and discovery efforts. The company's mission is to provide effective therapeutic solutions aimed at defeating cancer.

The Public Health Company

Seed Round in 2021
The Public Health Company is a pioneering firm that specializes in biosecurity solutions, offering a SaaS-enabled platform designed for the management of bio-risks. Founded in 2020 and headquartered in Palo Alto, California, the company leverages advanced technology and expert knowledge to address the challenges of enterprise risk management. Its platform focuses on identifying and mitigating physical world threats across various applications, providing clients with actionable and predictive intelligence. This enables organizations to implement dynamic risk management strategies efficiently and effectively, enhancing their preparedness against potential biohazards.

TAE Technologies

Venture Round in 2021
Founded in 1998, TAE Technologies is dedicated to developing clean fusion energy through advanced particle accelerator and plasma physics. Its mission is to create a sustainable energy source with no harmful byproducts.

Auditoria.AI

Series A in 2021
Auditoria.AI, Inc. is a technology company based in Santa Clara, California, founded in 2019. It specializes in providing innovative financial solutions for enterprise accounting and audit, utilizing advanced artificial intelligence and machine learning technologies. The company focuses on enhancing compliance and automating finance back-office processes through its flagship product, which employs natural language processing and predictive analytics. By streamlining operations and reducing redundancy, Auditoria.AI aims to support finance teams in making informed, data-driven decisions and improving overall efficiency.

Graphite Bio

Series B in 2021
Graphite Bio is a clinical-stage gene editing company focused on targeted DNA integration to treat serious diseases. Its platform aims to precisely insert, repair, or replace genetic sequences by integrating therapeutic cargoes at predefined genomic locations, enabling correction of mutations or replacement of disease-causing genes while preserving normal regulatory control. Based in South San Francisco, the company pursues high-efficiency precision gene editing to address underlying causes of disease.

Amunix

Series B in 2021
Amunix Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to discovering and developing innovative protein and peptide therapeutics aimed at treating cancer. The company employs several proprietary platforms, including XTEN for extending drug half-life, XPAT for analyzing protease activity in the tumor microenvironment, and ProTIA, which focuses on immuno-oncology therapeutics. Amunix's product pipeline includes prodrugs and transformative T-cell engagers designed to activate the immune system against solid tumors. The company collaborates with various academic, biotechnology, and pharmaceutical sectors, maintaining strategic partnerships with organizations such as Janssen and Biogen-Idec. Founded in 2006 and headquartered in Mountain View, California, Amunix strives to deliver breakthroughs that can harness the immune system to combat cancer more effectively.

Decodable

Seed Round in 2021
Decodable is a serverless data integration and engineering platform focused on streaming data, founded in 2021 by Eric Sammer and headquartered in San Francisco, California. The company offers a software solution that enables applications and data engineers to construct complex data pipelines efficiently. Its platform facilitates seamless connections to various existing messaging, storage, and database systems, allowing users to rapidly collect, process, and deliver data to both offline and online systems. Through its innovative approach, Decodable aims to simplify the management of streaming data, enhancing the capabilities of organizations in handling real-time data flows.

Artiva Biotherapeutics

Series B in 2021
Artiva Biotherapeutics, Inc. is a San Diego-based biotechnology company focused on developing and manufacturing cellular immunotherapies for cancer treatment. Founded in 2019, Artiva specializes in off-the-shelf, allogeneic natural killer (NK) cell therapies aimed at treating both hematologic cancers and solid tumors. The company's product pipeline includes therapies that target CD20 and CD19 in B-cell lymphomas, as well as HER2 in various solid tumors. Artiva is committed to harnessing the therapeutic potential of NK cells while addressing challenges in their scalability and manufacturing. Its mission centers on delivering effective and safe cell therapies that are readily accessible to cancer patients in need.

Sitka

Series A in 2021
Sitka is a healthcare technology company that develops a telehealth and video platform to connect patients with clinicians across specialties. The platform enables primary care providers to access a virtual specialty network and supports collaboration among endocrinology, neurology, orthopedics, pulmonology, rheumatology, and related fields. It also offers personalized, one-on-one consultation on imaging results, such as MRI, with board-certified musculoskeletal doctors to inform care decisions. The company aims to streamline the care cycle, upskill primary care, and improve patient outcomes through accessible, expert guidance. Sitka originated in San Francisco in 2018.

RayzeBio

Series B in 2020
RayzeBio, Inc. is a biotechnology company based in San Diego, California, founded in 2020. The company specializes in developing tumor-targeted small molecule medicines that leverage radioisotopes to improve cancer treatment outcomes. RayzeBio focuses on creating innovative radiopharmaceuticals, particularly utilizing alpha-emitting radioisotopes like Actinium-225, to target solid tumors effectively. With a robust pipeline of drug candidates, RayzeBio is committed to addressing significant market opportunities in oncology through late-stage clinical programs, development initiatives, and discovery efforts. The company's mission is to provide effective therapeutic solutions aimed at defeating cancer.

Luma

Seed Round in 2020
Luma, Inc. is a technology company that specializes in designing and developing a platform for managing events. Incorporated in 2020 and based in California, Luma offers a range of features including ticket sales, attendance tracking, event promotion, and analytics. The platform facilitates virtual classes, live shows, and community engagement through tools that allow users to invite attendees and share content. Luma aims to enhance the experience of hosting and attending online events, providing a seamless environment for both organizers and participants.

Federation Bio

Series A in 2020
Federation Bio Inc., established in 2018 and headquartered in South San Francisco, California, specializes in the development of microbial therapeutics targeting diseases where the human microbiome holds curative potential. The company's platforms focus on secondary hyperoxaluria and explore treatments for metabolic disorders, immune diseases, and cancer. Federation Bio's approach involves leveraging naturally occurring or engineered bacteria alongside a diverse community of supportive bacteria to drive engraftment and durable therapeutic responses.

Kinnate Biopharma

Series C in 2020
Kinnate Biopharma Inc. is a biopharmaceutical company dedicated to the discovery and development of small molecule kinase inhibitors aimed at treating genomically defined cancers. Established in 2018 and headquartered in San Diego, California, the company focuses on precision oncology therapeutics, leveraging its expertise in structure-based drug discovery and translational research. Kinnate's lead product candidate, KIN002787, is a rapidly accelerated fibrosarcoma inhibitor currently in preclinical development for lung cancer, melanoma, and other solid tumors. Additionally, the company is advancing other preclinical candidates, including KIN003, which targets cancer-associated alterations in FGFR2 and FGFR3 genes, and a Cyclin-Dependent Kinase 12 inhibitor in the KIN004 program. Kinnate Biopharma is committed to developing targeted therapeutics for underserved patient populations, aiming to expand the reach of precision medicine in cancer treatment.

VelosBio

Series B in 2020
VelosBio, Inc. is a clinical-stage biopharmaceutical company based in San Diego, California, focused on developing innovative antibody-drug conjugates (ADCs) to treat various hematological cancers and solid tumors. Established in 2017, the company specializes in therapies that target receptor tyrosine kinase-like orphan receptor 1 (ROR1), a protein present on many cancerous cells but absent in normal tissues, making it a promising target for cancer treatment. VelosBio's lead product, VLS-101, is an ROR1-directed ADC designed for patients with both hematologic and solid tumor malignancies. The company's approach aims to provide novel targeted therapies that can be utilized as monotherapy or in combination with other treatments across a wide array of cancer types.

Iris Medicine

Seed Round in 2020
Founded in 2019 and headquartered in Palo Alto, California, Iris Medicine specializes in developing RNA therapeutics for treating genetic diseases. Its proprietary platform targets repeat sequences in RNA transcripts to selectively modulate them, focusing on neurological disorders.

RefleXion Medical

Series D in 2020
RefleXion Medical Inc. is a medical equipment company based in Hayward, California, focused on revolutionizing cancer treatment through its biologically-guided radiotherapy system (BgRT). This innovative technology allows tumors to continuously signal their location during treatment, enabling the simultaneous targeting of multiple tumors, even in cases of metastasized cancer. The RefleXion X1 machine is cleared for various forms of radiotherapy, including stereotactic body radiotherapy, stereotactic radiosurgery, and intensity-modulated radiotherapy. The BgRT system utilizes positron-emission tomography (PET) imaging data to synchronize tumor location information with the linear accelerator, allowing for real-time adjustments in treatment delivery with subsecond latency. RefleXion Medical has established strategic collaborations with Telix Pharmaceuticals Limited and HealthMyne Inc. since its incorporation in 2009.

ABL Space Systems

Venture Round in 2020
ABL Space Systems is a company that designs and manufactures rockets specifically for launching small satellites. Founded in 2017 and headquartered in El Segundo, California, ABL focuses on developing low-cost and reliable launch vehicles. Its primary product, the RS1 rocket, is capable of carrying payloads of up to 1,350 kilograms to Low Earth Orbit (LEO) and supports various configurations, including multi-manifest and dedicated deployments. Additionally, ABL has developed the GS0 ground system to facilitate rapid deployment and integration of launch operations at multiple locations. The company operates out of a 30,000 square foot facility dedicated to research, development, and production.

Lyra Health

Series C in 2020
Lyra Health operates a digital health platform that enhances mental health care for employees by connecting them with a curated network of therapists and coaches. Founded in 2015 and based in Burlingame, California, Lyra uses matching technology to pair individuals with suitable providers based on their needs and preferences. The platform offers live video therapy, coaching, and digital self-care tools, ensuring faster access to care and better outcomes compared to traditional plans. Lyra assesses treatment effectiveness using clinical measures like the PHQ-9 and GAD-7 for conditions such as anxiety and depression. This approach results in significantly more people receiving care and achieving improved mental health outcomes.

Amunix

Series A in 2020
Amunix Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to discovering and developing innovative protein and peptide therapeutics aimed at treating cancer. The company employs several proprietary platforms, including XTEN for extending drug half-life, XPAT for analyzing protease activity in the tumor microenvironment, and ProTIA, which focuses on immuno-oncology therapeutics. Amunix's product pipeline includes prodrugs and transformative T-cell engagers designed to activate the immune system against solid tumors. The company collaborates with various academic, biotechnology, and pharmaceutical sectors, maintaining strategic partnerships with organizations such as Janssen and Biogen-Idec. Founded in 2006 and headquartered in Mountain View, California, Amunix strives to deliver breakthroughs that can harness the immune system to combat cancer more effectively.

Virta Health

Series C in 2020
Virta Health is a San Francisco–based health technology company that specializes in treating type 2 diabetes through an online, physician-supported program. The company combines nutritional biochemistry, data science, and digital tools to deliver on-demand care via a continuous remote care platform, providing physicians and health coaches who guide patients to reduce blood sugar and lose weight without medications or surgery. Founded in 2014, Virta offers a treatment approach aimed at reversing type 2 diabetes and improving related metabolic and cardiovascular health.

Kyruus

Series D in 2020
Kyruus, Inc. is a Boston-based company that develops web-based software solutions aimed at optimizing physician networks for hospitals, health systems, and life science companies. Founded in 2010, Kyruus offers a suite of analytically driven products designed to enhance provider search and scheduling, ensuring that patients are matched with the most suitable healthcare providers. Key offerings include Kyruus Passport, which allows physicians to track their activity and productivity, and Kyruus Profiles, which enables administrators to analyze physician performance metrics. Additionally, the company provides Kyruus MDSeekyr, a platform for identifying high-value providers, and Kyruus Insight Reports, which help executives evaluate network activity and performance trends. By leveraging a proprietary provider data management platform, Kyruus enhances patient engagement and aligns provider supply with patient demand, ultimately improving the overall healthcare experience. Kyruus also maintains offices in San Francisco and New York.

Element Biosciences

Series B in 2020
Element Biosciences develops innovative genetic analysis tools for research and diagnostic markets. Founded in 2017, the company specializes in a disruptive DNA sequencing technology that offers high-quality data, workflow flexibility, and affordable access to next-generation sequencing.

Inscripta

Series D in 2019
Inscripta is a gene editing technology company developing scalable digital genome engineering based on CRISPR approaches. It offers MADzymes enzymes for precision editing and is building a benchtop platform comprising an instrument, consumables, software, and assays that enables automated, massively parallel, trackable editing of single cells. The platform aims to lower technical and licensing barriers, delivering push-button workflows and low-cost libraries of thousands of designer proteins, pathways, or genome variants, each with defined and trackable mutations. The company also pursues collaboration by making its MAD7 nuclease available free for research and development to broaden access and accelerate biological discovery.

Percipient.ai

Series B in 2019
Percipient.ai provides an artificial intelligence platform and services for national security missions, including Mirage, a machine learning platform that accelerates the analysis of full motion video, geospatial intelligence, and multi-source intelligence data to deliver decisive intelligence, and Mirage FMV, a module that recognizes, characterizes, and contextualizes persons, objects, and activities. Founded in 2017, the company is based in Santa Clara, California, with an additional office in Reston, Virginia.

Simbe Robotics

Series A in 2019
Simbe Robotics, Inc. is a San Francisco-based company established in 2014 that specializes in developing and manufacturing autonomous robotic solutions for the retail sector. Its flagship product, Tally, automates the labor-intensive process of shelf auditing by navigating store aisles to assess inventory levels. Tally identifies out-of-stock items, low stock items, misplaced products, and pricing discrepancies, providing valuable data to store staff. The robot operates safely alongside customers and employees during regular store hours, thereby enhancing operational efficiency and accuracy in retail environments.

Encoded Therapeutics

Series C in 2019
Encoded Therapeutics is a biotechnology company focused on precision gene therapies to treat a broad range of severe genetic disorders. It develops therapies and a platform that identifies human genome sequences that regulate gene expression using screening and computational approaches. The company's pipeline targets conditions across multiple pathways, including neurocircuitry, liver and metabolic disorders, neurodegeneration, and cardiovascular disease, aiming to help medical practitioners treat patients and improve outcomes. Based in South San Francisco, California, Encoded Therapeutics was founded in 2014 and was previously known as Encoded Genomics.

Element Biosciences

Series A in 2019
Element Biosciences develops innovative genetic analysis tools for research and diagnostic markets. Founded in 2017, the company specializes in a disruptive DNA sequencing technology that offers high-quality data, workflow flexibility, and affordable access to next-generation sequencing.

Concentric Analgesics

Series B in 2019
Concentric Analgesics is a biotechnology company developing non-opioid therapeutics for managing acute and chronic pain, with a focus on single local administration to target pain at the source while limiting systemic exposure. Its products aim to provide effective relief without numbness or weakness during procedures and to simplify ongoing care for patients with osteoarthritis and other conditions. The company is advancing treatments for post-surgical pain, chronic osteoarthritis pain, and refractory pain, including CA-008, an injectable capsaicin prodrug for acute post-surgical pain; CA-051 for epidural administration to treat refractory pain from cancer or amputation; and an injectable therapy for chronic pain associated with osteoarthritis. Founded in 2014, it is based in San Francisco, California.

Make School

Series B in 2019
Founded in 2011, Make School offers innovative higher education programs focused on computer science and software development. It partners with universities to provide instructional services, ensuring its curriculum remains relevant to the modern job market and accessible to students from diverse backgrounds.

Inscripta

Series C in 2019
Inscripta is a gene editing technology company developing scalable digital genome engineering based on CRISPR approaches. It offers MADzymes enzymes for precision editing and is building a benchtop platform comprising an instrument, consumables, software, and assays that enables automated, massively parallel, trackable editing of single cells. The platform aims to lower technical and licensing barriers, delivering push-button workflows and low-cost libraries of thousands of designer proteins, pathways, or genome variants, each with defined and trackable mutations. The company also pursues collaboration by making its MAD7 nuclease available free for research and development to broaden access and accelerate biological discovery.

Inscripta

Series C in 2018
Inscripta is a gene editing technology company developing scalable digital genome engineering based on CRISPR approaches. It offers MADzymes enzymes for precision editing and is building a benchtop platform comprising an instrument, consumables, software, and assays that enables automated, massively parallel, trackable editing of single cells. The platform aims to lower technical and licensing barriers, delivering push-button workflows and low-cost libraries of thousands of designer proteins, pathways, or genome variants, each with defined and trackable mutations. The company also pursues collaboration by making its MAD7 nuclease available free for research and development to broaden access and accelerate biological discovery.

Skyryse

Series A in 2018
Skyryse develops FlightOS, a hardware and software operating system that enables safer, more capable, and accessible flight across various aircraft types. Founded in 2016, the company is headquartered in Los Angeles, California.

ShockWave Medical

Series D in 2018
ShockWave Medical is a medical device company focused on developing and commercializing intravascular lithotripsy technology to treat calcified plaque in peripheral vascular, coronary vascular, and valvular diseases. The company markets lithoplasty catheters, including M5 for above-the-knee peripheral artery disease, C2 for coronary artery disease, and S4 for below-the-knee lesions, designed to modify calcium and improve vessel compliance before angioplasty or stent delivery. Its sonic pressure wave technology aims to limit injury to healthy tissue and facilitate procedures such as transcatheter coronary interventions and valve therapies. The business serves interventional cardiologists, vascular surgeons, and interventional radiologists through a direct sales force and distributors. It operates in the United States, Germany, the rest of Europe, and other international markets. Founded in 2009, ShockWave Medical is headquartered in Santa Clara, California.

Shape Security

Series E in 2018
Shape Security, Inc. is a cybersecurity company specializing in protecting web and mobile applications from automated cyber-attacks. Founded in 2011 and headquartered in Santa Clara, California, with additional offices in Sydney and London, the company utilizes AI-powered defenses to mitigate fraud, abuse, and attacks on applications and APIs. Its key products include ShapeShifter Elements, which enforces real-time security measures, and Shape Protection Manager, a cloud-based management tool for its services. Shape Security has successfully deflected over $1 billion in fraud losses across various sectors, including retail, finance, travel, healthcare, and government, safeguarding organizations from reputational damage and financial losses.

Atom Computing

Seed Round in 2018
Atom Computing Inc. is a technology company based in Berkeley, California, focused on the development of scalable quantum computers utilizing individual atoms. Founded in 2018, the company leverages the quantum mechanical properties of these atoms to process information and tackle complex problems that are beyond the capabilities of traditional computing. Atom Computing's innovative approach enables precise control, scaling, and stabilization of atoms, allowing quantum engineers and researchers to conduct advanced calculations in various fields, including drug design, computational chemistry, and other areas of general computing.

Renew Health

Series A in 2018
Renew Health, established in 2016 and headquartered in San Francisco, operates a cloud-based platform focused on providing senior benefits tailored for the baby boomer generation. The company addresses inefficiencies in the healthcare system related to medication management, which accounts for a significant portion of healthcare spending. Renew Health aims to align its business model with the interests of health plans and patients by charging fixed fees on a per-member and per-task basis for medication administration. This approach allows the company to pass through drug-related costs and rebates to health plans while also offering clinical services designed to enhance patient outcomes and reduce overall healthcare costs. By prioritizing value for payers and patients, Renew Health seeks to address the misaligned incentives often found in traditional pharmaceutical benefits management.

Lyra Health

Series B in 2018
Lyra Health operates a digital health platform that enhances mental health care for employees by connecting them with a curated network of therapists and coaches. Founded in 2015 and based in Burlingame, California, Lyra uses matching technology to pair individuals with suitable providers based on their needs and preferences. The platform offers live video therapy, coaching, and digital self-care tools, ensuring faster access to care and better outcomes compared to traditional plans. Lyra assesses treatment effectiveness using clinical measures like the PHQ-9 and GAD-7 for conditions such as anxiety and depression. This approach results in significantly more people receiving care and achieving improved mental health outcomes.

Doctor On Demand

Series C in 2018
Doctor On Demand, Inc. is a telemedicine company that provides an online platform for patients to consult with licensed healthcare providers, including doctors and psychologists, through video calls. Established in 2012 and headquartered in San Francisco, California, the company offers a range of medical services addressing conditions such as cold and flu, allergies, anxiety, and chronic illnesses. Its platform, Synapse, caters to health plans and employers, facilitating both on-demand and scheduled visits via smartphones, tablets, or computers. Doctor On Demand emphasizes accessibility and quality care, enabling patients to easily receive medical attention and prescriptions when needed. Additionally, the company has offices in Minneapolis, Minnesota, and Washington, D.C.

Kyruus

Corporate Round in 2018
Kyruus, Inc. is a Boston-based company that develops web-based software solutions aimed at optimizing physician networks for hospitals, health systems, and life science companies. Founded in 2010, Kyruus offers a suite of analytically driven products designed to enhance provider search and scheduling, ensuring that patients are matched with the most suitable healthcare providers. Key offerings include Kyruus Passport, which allows physicians to track their activity and productivity, and Kyruus Profiles, which enables administrators to analyze physician performance metrics. Additionally, the company provides Kyruus MDSeekyr, a platform for identifying high-value providers, and Kyruus Insight Reports, which help executives evaluate network activity and performance trends. By leveraging a proprietary provider data management platform, Kyruus enhances patient engagement and aligns provider supply with patient demand, ultimately improving the overall healthcare experience. Kyruus also maintains offices in San Francisco and New York.

Virta Health

Series B in 2018
Virta Health is a San Francisco–based health technology company that specializes in treating type 2 diabetes through an online, physician-supported program. The company combines nutritional biochemistry, data science, and digital tools to deliver on-demand care via a continuous remote care platform, providing physicians and health coaches who guide patients to reduce blood sugar and lose weight without medications or surgery. Founded in 2014, Virta offers a treatment approach aimed at reversing type 2 diabetes and improving related metabolic and cardiovascular health.

RefleXion Medical

Series C in 2018
RefleXion Medical Inc. is a medical equipment company based in Hayward, California, focused on revolutionizing cancer treatment through its biologically-guided radiotherapy system (BgRT). This innovative technology allows tumors to continuously signal their location during treatment, enabling the simultaneous targeting of multiple tumors, even in cases of metastasized cancer. The RefleXion X1 machine is cleared for various forms of radiotherapy, including stereotactic body radiotherapy, stereotactic radiosurgery, and intensity-modulated radiotherapy. The BgRT system utilizes positron-emission tomography (PET) imaging data to synchronize tumor location information with the linear accelerator, allowing for real-time adjustments in treatment delivery with subsecond latency. RefleXion Medical has established strategic collaborations with Telix Pharmaceuticals Limited and HealthMyne Inc. since its incorporation in 2009.

Percipient.ai

Series A in 2018
Percipient.ai provides an artificial intelligence platform and services for national security missions, including Mirage, a machine learning platform that accelerates the analysis of full motion video, geospatial intelligence, and multi-source intelligence data to deliver decisive intelligence, and Mirage FMV, a module that recognizes, characterizes, and contextualizes persons, objects, and activities. Founded in 2017, the company is based in Santa Clara, California, with an additional office in Reston, Virginia.

Inscripta

Series C in 2018
Inscripta is a gene editing technology company developing scalable digital genome engineering based on CRISPR approaches. It offers MADzymes enzymes for precision editing and is building a benchtop platform comprising an instrument, consumables, software, and assays that enables automated, massively parallel, trackable editing of single cells. The platform aims to lower technical and licensing barriers, delivering push-button workflows and low-cost libraries of thousands of designer proteins, pathways, or genome variants, each with defined and trackable mutations. The company also pursues collaboration by making its MAD7 nuclease available free for research and development to broaden access and accelerate biological discovery.

Dynamic Signal

Series E in 2018
Dynamic Signal, established in 2010 and headquartered in San Bruno, California, specializes in employee communication and engagement. Its platform connects companies with their employees, facilitating the dissemination of timely, relevant content across various channels and devices. This enhances productivity, fosters employee engagement, and amplifies corporate messaging. Dynamic Signal serves hundreds of global enterprises, including 85 Fortune 500 companies, such as IBM, Salesforce, and Edelman.

Skyryse

Series A in 2017
Skyryse develops FlightOS, a hardware and software operating system that enables safer, more capable, and accessible flight across various aircraft types. Founded in 2016, the company is headquartered in Los Angeles, California.

Tricida

Series D in 2017
Tricida, Inc. is a late-stage pharmaceutical company based in South San Francisco, California, established in 2013. The company specializes in the development and commercialization of TRC101, a non-absorbed, orally-administered polymer designed to treat metabolic acidosis in patients with chronic kidney disease (CKD). Metabolic acidosis, a common complication of CKD, can accelerate kidney deterioration and is associated with serious health risks, including muscle wasting and loss of bone density. Tricida has successfully completed a Phase 3, double-blind, placebo-controlled trial of TRC101, positioning the company to address a significant unmet medical need in CKD management through the innovative approach of binding and removing acid from the gastrointestinal tract.

Stride Health

Series B in 2017
Stride Health, Inc. is a health benefits platform that specializes in providing affordable health coverage options for independent workers and part-time employees in the United States. The company offers a range of services, including dental plans, doctor and prescription insurance plans, and various health coverage options tailored to meet the needs of its customers. Stride Health simplifies the enrollment process by guiding users through selecting the most cost-effective health plans, aiming to optimize their tax benefits and enhance their take-home pay. Founded in 2013 and based in San Francisco, California, the company was previously known as Covered, Inc. and rebranded to Stride Health, Inc. in March 2013. Stride Health also provides personal advisory services to assist clients in navigating the complexities of their health insurance options.

Virta Health

Series A in 2017
Virta Health is a San Francisco–based health technology company that specializes in treating type 2 diabetes through an online, physician-supported program. The company combines nutritional biochemistry, data science, and digital tools to deliver on-demand care via a continuous remote care platform, providing physicians and health coaches who guide patients to reduce blood sugar and lose weight without medications or surgery. Founded in 2014, Virta offers a treatment approach aimed at reversing type 2 diabetes and improving related metabolic and cardiovascular health.

Inscripta

Series B in 2017
Inscripta is a gene editing technology company developing scalable digital genome engineering based on CRISPR approaches. It offers MADzymes enzymes for precision editing and is building a benchtop platform comprising an instrument, consumables, software, and assays that enables automated, massively parallel, trackable editing of single cells. The platform aims to lower technical and licensing barriers, delivering push-button workflows and low-cost libraries of thousands of designer proteins, pathways, or genome variants, each with defined and trackable mutations. The company also pursues collaboration by making its MAD7 nuclease available free for research and development to broaden access and accelerate biological discovery.

Evident.IO

Series C in 2017
Evident.io, Inc. is a security management company based in Pleasanton, California, that specializes in cloud infrastructure security. Founded in 2013, the company provides a software platform designed to enhance security and compliance in public cloud environments, particularly for Amazon Web Services. Its agentless and API-centric Evident Security Platform continuously monitors cloud resources, identifying security misconfigurations, vulnerabilities, and compliance risks. By delivering actionable intelligence in a user-friendly format, Evident.io enables organizations of all sizes to effectively manage their security posture and swiftly remediate identified risks. The company's focus on making cloud security accessible and efficient caters to the needs of DevOps professionals, cloud engineers, and IT risk managers, thus bridging the gap between agile development and robust security practices. In 2018, Evident.io was acquired by Palo Alto Networks, further expanding its capabilities within the cybersecurity landscape.

Dynamic Signal

Series D in 2016
Dynamic Signal, established in 2010 and headquartered in San Bruno, California, specializes in employee communication and engagement. Its platform connects companies with their employees, facilitating the dissemination of timely, relevant content across various channels and devices. This enhances productivity, fosters employee engagement, and amplifies corporate messaging. Dynamic Signal serves hundreds of global enterprises, including 85 Fortune 500 companies, such as IBM, Salesforce, and Edelman.

ShockWave Medical

Series C in 2016
ShockWave Medical is a medical device company focused on developing and commercializing intravascular lithotripsy technology to treat calcified plaque in peripheral vascular, coronary vascular, and valvular diseases. The company markets lithoplasty catheters, including M5 for above-the-knee peripheral artery disease, C2 for coronary artery disease, and S4 for below-the-knee lesions, designed to modify calcium and improve vessel compliance before angioplasty or stent delivery. Its sonic pressure wave technology aims to limit injury to healthy tissue and facilitate procedures such as transcatheter coronary interventions and valve therapies. The business serves interventional cardiologists, vascular surgeons, and interventional radiologists through a direct sales force and distributors. It operates in the United States, Germany, the rest of Europe, and other international markets. Founded in 2009, ShockWave Medical is headquartered in Santa Clara, California.

Intuity Medical

Venture Round in 2016
Intuity Medical, Inc. is a medical technology company specializing in blood glucose monitoring systems for diabetes management. Founded in 2002 and headquartered in Fremont, California, the company is known for its innovative POGO Automatic Blood Glucose Monitoring System. This system is the first FDA-cleared automatic, one-step blood glucose meter that integrates lancing, blood collection, and analysis into a single cartridge capable of performing ten tests. Intuity Medical aims to provide a convenient and discreet solution for patients who require regular blood glucose testing, enhancing their ability to manage their diabetes effectively. The company was previously known as Rosedale Medical, Inc. until it rebranded in June 2007.

Shape Security

Series D in 2016
Shape Security, Inc. is a cybersecurity company specializing in protecting web and mobile applications from automated cyber-attacks. Founded in 2011 and headquartered in Santa Clara, California, with additional offices in Sydney and London, the company utilizes AI-powered defenses to mitigate fraud, abuse, and attacks on applications and APIs. Its key products include ShapeShifter Elements, which enforces real-time security measures, and Shape Protection Manager, a cloud-based management tool for its services. Shape Security has successfully deflected over $1 billion in fraud losses across various sectors, including retail, finance, travel, healthcare, and government, safeguarding organizations from reputational damage and financial losses.

Beckon

Venture Round in 2016
Beckon, Inc. is a software company specializing in omnichannel analytics for marketers, founded in 2011 and headquartered in San Mateo, California. It offers a software-as-a-service platform that integrates marketing data to provide performance analytics and visualization solutions. Beckon's software delivers real-time marketing intelligence through automated data management, allowing marketers to gain total visibility into cross-channel performance. The platform features pre-built dashboards, scorecards, and key performance indicators, enabling users to make informed decisions swiftly and maximize return on investment. As of November 2018, Beckon operates as a subsidiary of Aclate, Inc. Its goal is to aid marketers in organizing complex data and effectively demonstrating the impact of marketing efforts on business outcomes.

Appthority

Series B in 2016
Appthority, Inc. is a company specializing in mobile application security solutions, founded in 2011 and headquartered in San Francisco, California. It is recognized as a leader in the Mobile Threat Defense category, providing a comprehensive solution known as Mobile Threat Protection (MTP). This solution helps enterprises safeguard their data and maintain employee privacy by addressing various mobile threats, including those from devices, applications, and networks. Appthority's offerings include threat detection, management, and intelligence, which equip security teams with the necessary tools to enhance visibility and control over mobile risks. The company has earned the trust of numerous Fortune 1000 companies, delivering best-in-class protection and ensuring that enterprise data remains private and secure. As of November 2018, Appthority operates as a subsidiary of NortonLifeLock Inc.

Jiff

Series C in 2016
Jiff, Inc. is a technology company that specializes in providing a HIPAA-compliant platform for the healthcare industry, enabling the creation of personalized and private communities of care. Founded in 2010 and headquartered in Mountain View, California, Jiff focuses on enhancing communication between healthcare professionals and patients through innovative tools. One of its notable products is JiffPad, an educational platform for iPads that transforms doctor-patient conversations and images into videos, facilitating easier sharing and understanding within the privacy of patients' homes. The company also offers solutions that engage employees by linking company benefits and incentives to healthy behaviors, leveraging familiar wearables and applications. Jiff has formed strategic alliances with firms such as Towers Watson & Co. and Mercer, furthering its mission to improve healthcare delivery and employee engagement. As of April 2017, Jiff operates as a subsidiary of Castlight Health, Inc.

Evident.IO

Series B in 2016
Evident.io, Inc. is a security management company based in Pleasanton, California, that specializes in cloud infrastructure security. Founded in 2013, the company provides a software platform designed to enhance security and compliance in public cloud environments, particularly for Amazon Web Services. Its agentless and API-centric Evident Security Platform continuously monitors cloud resources, identifying security misconfigurations, vulnerabilities, and compliance risks. By delivering actionable intelligence in a user-friendly format, Evident.io enables organizations of all sizes to effectively manage their security posture and swiftly remediate identified risks. The company's focus on making cloud security accessible and efficient caters to the needs of DevOps professionals, cloud engineers, and IT risk managers, thus bridging the gap between agile development and robust security practices. In 2018, Evident.io was acquired by Palo Alto Networks, further expanding its capabilities within the cybersecurity landscape.

PowerVision

Series D in 2016
PowerVision, Inc. is a medical device company based in Belmont, California, focused on developing advanced intraocular lenses (IOLs) designed to restore vision for individuals affected by presbyopia and cataracts. Established in 2002, the company has created the FluidVision accommodating intraocular lens technology, which simulates the natural function of a healthy eye. This innovative lens utilizes a small amount of fluid to adjust its shape dynamically, allowing for clear vision at various distances. PowerVision aims to address the vision challenges faced by millions, particularly the over 20 million individuals in the U.S. with cataracts and the more than 90 million affected by presbyopia. The FluidVision lens represents a significant advancement in vision correction, potentially freeing patients from the need for glasses or other vision correction methods. In 2019, PowerVision was acquired by Alcon Laboratories, Inc.

RefleXion Medical

Series B in 2016
RefleXion Medical Inc. is a medical equipment company based in Hayward, California, focused on revolutionizing cancer treatment through its biologically-guided radiotherapy system (BgRT). This innovative technology allows tumors to continuously signal their location during treatment, enabling the simultaneous targeting of multiple tumors, even in cases of metastasized cancer. The RefleXion X1 machine is cleared for various forms of radiotherapy, including stereotactic body radiotherapy, stereotactic radiosurgery, and intensity-modulated radiotherapy. The BgRT system utilizes positron-emission tomography (PET) imaging data to synchronize tumor location information with the linear accelerator, allowing for real-time adjustments in treatment delivery with subsecond latency. RefleXion Medical has established strategic collaborations with Telix Pharmaceuticals Limited and HealthMyne Inc. since its incorporation in 2009.

Spirox

Series C in 2016
Spirox, Inc. is a medical device company based in Menlo Park, California, that specializes in improving the quality of life for patients experiencing nasal obstruction due to nasal valve collapse (NVC). Founded in 2011 and formerly known as Nasoform LLC, Spirox has developed the LATERA absorbable nasal implant, which offers a minimally invasive solution for treating one of the most prevalent yet often overlooked causes of nasal obstruction. The LATERA implant is designed to address weakened lateral wall cartilage, providing ENT specialists and facial plastic surgeons with an effective option to alleviate nasal airway obstruction. As of 2017, Spirox operates as a subsidiary of Entellus Medical, Inc.

Appthority

Series B in 2016
Appthority, Inc. is a company specializing in mobile application security solutions, founded in 2011 and headquartered in San Francisco, California. It is recognized as a leader in the Mobile Threat Defense category, providing a comprehensive solution known as Mobile Threat Protection (MTP). This solution helps enterprises safeguard their data and maintain employee privacy by addressing various mobile threats, including those from devices, applications, and networks. Appthority's offerings include threat detection, management, and intelligence, which equip security teams with the necessary tools to enhance visibility and control over mobile risks. The company has earned the trust of numerous Fortune 1000 companies, delivering best-in-class protection and ensuring that enterprise data remains private and secure. As of November 2018, Appthority operates as a subsidiary of NortonLifeLock Inc.

Dollar Shave Club

Series D in 2015
Dollar Shave Club is a lifestyle brand and e-commerce company that develops and sells grooming products for men. It uses an exclusive R&D process that includes botanicals and chemists to create its own products at affordable prices. Founded in 2012 and based in Santa Monica, California, the company offers razors, blades, shave butter, aftershave liquids, face washes, wipes, and gift cards, primarily through a subscription model that provides convenient access to products at reasonable prices.

Lyra Health

Series A in 2015
Lyra Health operates a digital health platform that enhances mental health care for employees by connecting them with a curated network of therapists and coaches. Founded in 2015 and based in Burlingame, California, Lyra uses matching technology to pair individuals with suitable providers based on their needs and preferences. The platform offers live video therapy, coaching, and digital self-care tools, ensuring faster access to care and better outcomes compared to traditional plans. Lyra assesses treatment effectiveness using clinical measures like the PHQ-9 and GAD-7 for conditions such as anxiety and depression. This approach results in significantly more people receiving care and achieving improved mental health outcomes.

Audentes Therapeutics

Series C in 2015
Audentes Therapeutics, a clinical stage biotechnology company based in San Francisco, specializes in developing gene therapy products aimed at treating serious, life-threatening rare diseases resulting from single gene defects. The company is advancing several therapeutic candidates, including AT132 for X-linked myotubular myopathy, AT342 for Crigler-Najjar syndrome, and AT845, which is in preclinical studies for Pompe disease. Additionally, Audentes is developing vectorized antisense treatments for Duchenne muscular dystrophy and myotonic dystrophy type 1. It has established collaborative agreements with Genethon and the University of Pennsylvania to further research and commercialization efforts for these therapies. Founded in 2012, Audentes Therapeutics was acquired by Astellas Pharma in January 2020 and operates under the name Astellas Gene Therapies, focusing on gene therapy research, development, and future commercialization.

Cloudflare

Series D in 2015
Cloudflare, Inc. is a San Francisco-based software company that specializes in web performance and security services for businesses globally. It operates a cloud platform that integrates various network services, including security solutions such as Cloud Firewall, Bot Management, and Distributed Denial of Service protection. The company enhances website performance through its Content Delivery Network (CDN) and intelligent routing, while also providing optimization tools for content and images. Furthermore, Cloudflare offers reliability solutions like Load Balancing and DNS services, alongside security features aimed at protecting internal resources through Zero Trust Security and Secure Web Gateway. Its consumer offerings include a DNS resolver and a virtual private network (VPN) designed to secure mobile traffic. Cloudflare serves diverse industries, including technology, healthcare, financial services, and government, and was founded in 2009.

Kyruus

Series C in 2015
Kyruus, Inc. is a Boston-based company that develops web-based software solutions aimed at optimizing physician networks for hospitals, health systems, and life science companies. Founded in 2010, Kyruus offers a suite of analytically driven products designed to enhance provider search and scheduling, ensuring that patients are matched with the most suitable healthcare providers. Key offerings include Kyruus Passport, which allows physicians to track their activity and productivity, and Kyruus Profiles, which enables administrators to analyze physician performance metrics. Additionally, the company provides Kyruus MDSeekyr, a platform for identifying high-value providers, and Kyruus Insight Reports, which help executives evaluate network activity and performance trends. By leveraging a proprietary provider data management platform, Kyruus enhances patient engagement and aligns provider supply with patient demand, ultimately improving the overall healthcare experience. Kyruus also maintains offices in San Francisco and New York.

Dynamic Signal

Series C in 2015
Dynamic Signal, established in 2010 and headquartered in San Bruno, California, specializes in employee communication and engagement. Its platform connects companies with their employees, facilitating the dissemination of timely, relevant content across various channels and devices. This enhances productivity, fosters employee engagement, and amplifies corporate messaging. Dynamic Signal serves hundreds of global enterprises, including 85 Fortune 500 companies, such as IBM, Salesforce, and Edelman.

Doctor On Demand

Series B in 2015
Doctor On Demand, Inc. is a telemedicine company that provides an online platform for patients to consult with licensed healthcare providers, including doctors and psychologists, through video calls. Established in 2012 and headquartered in San Francisco, California, the company offers a range of medical services addressing conditions such as cold and flu, allergies, anxiety, and chronic illnesses. Its platform, Synapse, caters to health plans and employers, facilitating both on-demand and scheduled visits via smartphones, tablets, or computers. Doctor On Demand emphasizes accessibility and quality care, enabling patients to easily receive medical attention and prescriptions when needed. Additionally, the company has offices in Minneapolis, Minnesota, and Washington, D.C.

Lyra Health

Seed Round in 2015
Lyra Health operates a digital health platform that enhances mental health care for employees by connecting them with a curated network of therapists and coaches. Founded in 2015 and based in Burlingame, California, Lyra uses matching technology to pair individuals with suitable providers based on their needs and preferences. The platform offers live video therapy, coaching, and digital self-care tools, ensuring faster access to care and better outcomes compared to traditional plans. Lyra assesses treatment effectiveness using clinical measures like the PHQ-9 and GAD-7 for conditions such as anxiety and depression. This approach results in significantly more people receiving care and achieving improved mental health outcomes.

CytomX Therapeutics

Series D in 2015
CytomX Therapeutics is a clinical-stage oncology-focused biopharmaceutical company that develops proteolytically-activated antibodies based on its Probody technology platform. Probody therapeutics are designed to be activated by the tumor microenvironment, enabling targeted cancer immunotherapies with reduced activity in healthy tissues. The company advances antibody and antibody-drug conjugate programs such as CX-072 (PD-L1), CX-2009 (CD166-targeted PDC), BMS-986249 (CTLA-4 Probody), CX-2029 (CD71-targeted PDC), and BMS-986288 (CTLA-4 Probody) in clinical research, and maintains collaborations with AbbVie, Amgen, Bristol-Myers Squibb, ImmunoGen, Pfizer, and Astellas to develop Probody therapeutics. Founded in 2008 and headquartered in South San Francisco, the company aims to improve the precision and safety of antibody-based therapies for cancer and inflammatory diseases.

Shift Messenger

Seed Round in 2015
Shift Messenger, Inc. is a San Francisco-based company founded in 2014 that specializes in developing a mobile messaging application tailored for shift workers in industries such as retail, restaurants, and healthcare. The application facilitates communication among employees, allowing them to swap shifts, manage their schedules, and address everyday work challenges. By providing a platform for workers to connect with their colleagues and stay informed about workplace updates, Shift Messenger aims to enhance the professional lives of shift workers and foster a sense of community within the workplace.

Jiff

Series C in 2015
Jiff, Inc. is a technology company that specializes in providing a HIPAA-compliant platform for the healthcare industry, enabling the creation of personalized and private communities of care. Founded in 2010 and headquartered in Mountain View, California, Jiff focuses on enhancing communication between healthcare professionals and patients through innovative tools. One of its notable products is JiffPad, an educational platform for iPads that transforms doctor-patient conversations and images into videos, facilitating easier sharing and understanding within the privacy of patients' homes. The company also offers solutions that engage employees by linking company benefits and incentives to healthy behaviors, leveraging familiar wearables and applications. Jiff has formed strategic alliances with firms such as Towers Watson & Co. and Mercer, furthering its mission to improve healthcare delivery and employee engagement. As of April 2017, Jiff operates as a subsidiary of Castlight Health, Inc.

Stride Health

Series A in 2015
Stride Health, Inc. is a health benefits platform that specializes in providing affordable health coverage options for independent workers and part-time employees in the United States. The company offers a range of services, including dental plans, doctor and prescription insurance plans, and various health coverage options tailored to meet the needs of its customers. Stride Health simplifies the enrollment process by guiding users through selecting the most cost-effective health plans, aiming to optimize their tax benefits and enhance their take-home pay. Founded in 2013 and based in San Francisco, California, the company was previously known as Covered, Inc. and rebranded to Stride Health, Inc. in March 2013. Stride Health also provides personal advisory services to assist clients in navigating the complexities of their health insurance options.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.